Eva Hellström-Lindberg

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian et al. · Nature Medicine · 2020 · 606 citations · Full text

Hematological Malignancy, Chromatin, Genome Stability +11

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · New England Journal of Medicine · 2020 · 519 citations · Full text

Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

Eva Hellström-Lindberg, Tomas Ahlgren, Yves Béguin et al. · Blood · 1998 · 306 citations · Full text

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF

Martin Jädersten, Scott Montgomery, Ingunn Dybedal et al. · Blood · 2005 · 203 citations · Full text

Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML

Andreas T. Björklund, Mattias Carlsten, Ebba Sohlberg et al. · Clinical Cancer Research · 2018 · 182 citations · Full text